We have defined 18 chromosomal regions in which allelic losses were frequent among breast cancers. We examined whether specific allelic losses might correlate with any clinicopathological factors.
We tested DNA from matched normal and tumor tissues for loss of heterozygosity (LOH) at 18 microsatellite loci from a cohort of 504 patients who had undergone surgery for breast cancer.
LOH at 3pl4.3 correlated with a larger size of tumor (greater than 2 cm). LOH at 1p22, 3p25.1, 3pl4.3, or 17q21.1 correlated with loss of estrogen receptors. LOH at as many as eleven regions correlated with loss of progesterone receptor, suggesting that these represent general phenomena associated with progression of cancer. Above all, allelic losses at llq23-24,13ql2,17pl3.3, or 22ql3 significantly correlated with lymph-node metastasis (llq23-24,p = 0.0042; 13ql2,p = 0.0207; 17pl3.3,p = 0.0478; 22ql3,p = 0.0162).
These results suggest that some clinical characteristics of breast cancers are determined by loss of tumor suppressor genes present at specific chromosome regions. Especially, LOH at llq23-24, 13ql2, 17pl3.3, and 22ql3 is a significant predictor of lymph-node metastasis for patients who have undergone surgery for breast cancer, and may serve as a negative prognostic indicator.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Sat:o T, Tanigami A, Yamakawa K,et al: Allelotype of breast cancer:cumulat:ive allele losses promote tumor progression in primary breast cancer.Cancer Res 50: 7184–7189, 1990.
Sat:o T, Akiyama F, Sakamoto G,et al: Accumulat:ion of genetic alterat:ions and progression of primary breast cancer.Cancer Res 51: 5794–5799, 1991.
Takita K, Sat:o T, Miyagi M,et al: Correlat:ion of loss of alleles on the short arms of chromosomes 11 and 17 with metastasis of primary breast cancer to lymph nodes.Cancer Res 52: 3914–3917, 1992.
Saito H, Inazawa J, Saito S,et al: Detailed deletion mapping of chromosome 17q in ovarian and breast cancers:2-cM region on 17q21.3 often and commonly deleted in tumors.Cancer Res 53: 3382–3385, 1993.
Harada Y, Kat:agiri T, Ito I,et al: Genetic studies of 457 breast cancers. Clinicopat:hologic parameters compared with genetic alterat:ions.Cancer 74: 2281–2286, 1994.
Ito I, Yoshimoto M, Iwase T,et al: Associat:ion of genetic alterat:ions on chromosome 17 and loss of hormone receptors in breast cancer.Br J Cancer 71: 438–441, 1995.
Tsukamoto K, Ito N, Yoshimoto M,et al: Two distinct commonly deleted regions on chromosome 13q suggest involvement of BRCA2 and retinoblastoma genes in sporadic breast carcinomas.Cancer 78: 1929–1934, 1996.
Yokota T, Mat:sumoto S, Yoshimoto M,et al: Mapping of breast cancer tumor suppressor gene locus to a 4-cM interval on chromosome 18q21.Jpn J Cancer Res 88: 959–964, 1997.
Nakat:a T, Yoshimoto M, Kasumi F,et al: Identificat:ion of a new commonly deleted region within a 2-cM interval of llpll in breast cancers.Eur J Cancer 34: 417–421, 1998.
Emi M, Yoshimoto M, Sat:o T,et al: Allelic loss at Ip34, 13ql2, 17pl3.3, and 17q21.1 correlat:es with poor postoperat:ive prognosis in breast cancer.Genes Chrom Cancer 26: 134–141, 1999.
Japanese Breast Cancer Society. General rules for clinical and pat:hological recording of breast cancer.Jpn J Surg 19: 612–632, 1989.
Iida A, Yoshimoto M, Kasumi F,et al: Localization of breast cancer tumor-suppressor gene to a 3-cM interval within chromosomal region 16q22.Br J Cancer 75: 264–267, 1997.
Dib C, Faure S, Fizames C,et al: A comprehensive genetic map of the human genome based on 5,264 microsatellites.Nature 380: 152–154, 1996.
Laake K, Launonen V, Niederacher D,et al: Loss of heterozygosity at:1lq23.1 and survival in breast cancerresults of a large European study. Breast Cancer Somatic Genetics Consortium.Genes Chrom Cancer 25: 212–221, 1999.
Winqvist R, Hampton GM, Mannermaa A,et al: Loss of heterozygosity for chromosome 11 in primary human breast tumors is associated with poor survival after metastasis.Cancer Res 55: 2660–2664, 1995.
Wooster R, Bignell G, Lancaster J,et al: Identificat:ion of the breast cancer susceptibility gene BRCA2.Nat:ure 378: 789–792, 1995.
Cornelis RS, Devilee P, Van Vliet M,et al: Allele loss patterns on chromosome 17q in 109 breast carcinomas indicate at least two distinct target regions.Oncogene 8: 781–785, 1993.
Cropp CS, Champeme MH, Lidereau R,et al: Identification of three regions on chromosome 17q in primary human breast carcinomas which are frequently deleted.Cancer Res 53: 5617–5619, 1993.
Nagai MA, Yamamoto L, Salaorni S,et al: Detailed deletion mapping of chromosome segment 17ql2-21 in sporadic breast tumors.Genes Chrom Cancer 11: 58–62, 1994.
Kerangueven F, Allione F, Noguchi T,et al: Patterns of loss of heterozygosity at:loci from chromosome arm 13q suggest a possible involvement of BRCA2 in sporadic breast tumors.Genes Chrom Cancer 13: 291–294, 1995.
Coles C, Condie A, Chetty U,et al: p 53 mutations in breast cancer.Cancer Res 52: 5291–5298, 1992.
Iida A, Kurose K, Isobe R,et al: Mapping of a new target region of allelic loss to a 2-cM interval at:22ql3.1 in primary breast cancer.Genes Chrom Cancer 21: 108–112, 1998.
Castells A, Gusella JF, Ramesh V,et al:A region of deletion on chromosome 22ql3 is common to human breast and colorectal cancers.Cancer Res 60: 2836–2839, 2000.
Hirano A, Utada Y, Haga S,et al: Allelic losses as prognostic markers for breast cancers.Int J Clin Oncol 6: 6–12, 2001.
Reprint requests to Mitsuru Emi, Department of Molecular Biology, Institute of Gerontology, Nippon Medical School, 1-396, Kosugi-cho, Nakahara-ku, Kawasaki 21 1-8533, Japan.
About this article
Cite this article
Nagahata, T., Hirano, A., Utada, Y. et al. Correlation of allelic losses and clinicopathological factors in 504 primary breast cancers. Breast Cancer 9, 208–215 (2002). https://doi.org/10.1007/BF02967591
- Breast cancer
- Loss of heterozygosity
- Tumor suppressor gene
- Human chromosomes
- Clinicopathological factor